Previous 10 | Next 10 |
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases PR Newswire New $6.5 million commitment will help strengthen systems to improve health outcomes across resource-limited areas in India GENEVA , May 2...
2024-05-29 05:20:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...
2024-05-28 21:19:27 ET Summary Chase Coleman's Tiger Global Management 13F portfolio value increased from $14.1B to $18.3B this quarter. The largest five positions in the portfolio are Meta Platforms, Microsoft, Alphabet, Apollo Global, and Amazon.com. New stakes include Liber...
2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...
2024-05-28 14:36:30 ET Summary Calamos Global Dynamic Income Fund offers high-income and geographic diversification, without sacrificing equity exposure. The fund's distribution yield of 9.00% is lower than its peers, but it has delivered strong recent performance and total return...
2024-05-28 10:49:02 ET More on the markets BofA says a signal to sell global equities is closer to lighting up Nasdaq, S&P, Dow are mixed following long weekend News have trended negatively against the ACWI - BofA Ignore The Weather Vanes UBS Inve...
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire INDIANAPOLIS , May 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on ...
2024-05-28 08:30:00 ET Summary Novo Nordisk stock has easily outperformed the market over the past year. Novo Nordisk's growth potential through its weight loss drugs is expanding. Competition from rivals like Eli Lilly and Amgen could impact demand and pricing dynamics in the...
2024-05-28 04:39:00 ET Eli Lilly (NYSE: LLY) stock is already up by about 90% over the past year, and it could climb even higher. BMO Capital analyst Evan Seigerman recently raised his price target to $1,001 per share, which implies a gain of about 24% from recent prices. Seiger...
2024-05-27 07:02:07 ET Summary Altimmune is developing an anti-obesity drug, Pemvidutide, that shows promising results in targeting fat mass and promoting weight loss. The obesity treatment market is expected to grow exponentially, reaching $77 billion by 2030, creating a signific...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 15:13:21 ET Eli Lilly & Co (NYSE: LLY) has recently experienced a dramatic $123 billion decline in market value. This significant drop follows positive developments from competitors, notably Viking Therapeutics Inc and Roche Holding AG, who made announcements regarding th...
2024-07-29 09:20:00 ET While the market for anti-obesity medicines is characterized today by a fight between Novo Nordisk 's (NYSE: NVO) drug Wegovy and Eli Lilly 's (NYSE: LLY) drug Zepbound, that won't always be the case. Over the coming years, the competitive dynamics of ...
2024-07-29 07:30:00 ET When a major player announces good news in a lucrative market like weight loss drugs, it's often enough to drive shares of competitors down based on the assumption that they will have struggles ahead. That's just what happened after an announcement by Roche Hold...